Allergen immunotherapy (AIT) modulates the immune system to prevent and relieve allergic symptoms. Unlike allergen avoidance and medication to control symptoms, AIT targets the underlying pathophysiology of allergic diseases. AIT is now considered a type of therapeutic vaccination. This article focuses on the current regulatory environ - ment in the EU and the special considerations in designing clinical trials evaluating AIT products.